AMETEK reports Q1 2026 results tomorrow morning with options traders displaying their most call-heavy positioning in months — a notable setup heading into a print where the tariff and industrial-demand backdrop remains firmly in focus.
The clearest signal this week is in the options market. The put/call ratio has dropped to 0.477, nearly a full standard deviation below its 20-day average of 0.54. That makes it one of the more bullish readings in recent weeks, a sharp pivot from mid-April when the PCR was running above 0.68 amid broader industrial sector anxiety. The shift toward calls suggests conviction has rebuilt since the tariff-driven turbulence of early April — though the 52-week range of 0.25 to 2.14 puts the current reading closer to the optimistic end without yet touching extremes. RSI14 is a neutral 51, which reinforces the picture of a market balanced rather than overextended.
Short interest is a sideshow here, not the headline. At 1.4% of the free float — flat on the day and up just 0.2% on the week — there is no meaningful bearish conviction in the lending market. What is worth noting is that the short position has grown roughly 21% over the past month, climbing steadily from around 2.5 million shares in mid-March to just over 3.24 million now. That build came during the broader market dislocation in early April, and it has since stabilised. Borrow conditions are entirely loose: cost to borrow is 0.50%, and availability is ample across the lending pool. The short-score of 30.4 ranks in the 65th percentile of the universe — elevated relative to its own recent history but nowhere near distressed territory.
The Street enters earnings cautiously constructive. The mean analyst price target sits at $250, implying roughly 9% upside from the current $228.95. Recent analyst activity has been mixed in direction. Morgan Stanley lifted its target to $235 in mid-March while holding Equal-Weight, a signal that the firm sees limited re-rating potential even after improving estimates. BMO initiated in late March with an Outperform and a $253 target, adding a fresh bullish voice. Baird, however, trimmed to $235 while staying Neutral — a soft read on near-term catalysts. The bear case centres on tariff-driven capital spending caution and potential softness in AMETEK's aerospace and industrial verticals. Bulls point to a record backlog, strong free cash flow — operating cash flow came in at $459 million in the latest quarter — and the company's track record of bolt-on M&A as durable earnings drivers. The PE has expanded roughly 2.3 points over the past month to 27.7x, reflecting both the stock's recovery and the market's willingness to pay for quality industrial compounders.
Institutional ownership offers the firmest backstory. Vanguard and BlackRock together hold over 20% of shares. Wellington Management added a notable 2.1 million shares as recently as February, the largest change among top holders. That kind of active buying from a major long-only manager provides a structural floor beneath the stock and signals fundamental conviction rather than passive drift. On the insider side, the late-March selling by the CEO and a cluster of senior executives — coordinated on March 20 at around $209 — reads as routine plan-driven activity rather than a fundamental signal. The net 90-day insider balance turned slightly positive at roughly $2.1 million, driven by award grants.
Prior earnings reactions have been muted. The February 2026 print produced a next-day move of just +0.05%, though the stock drifted modestly higher over the following week. The move a year earlier was also contained, with a one-day gain of 1.6% fading to essentially flat by day five. With a market cap of $53.4 billion and earnings consistency baked into the multiple, AMETEK does not trade as a high-beta earnings event — the question tomorrow is less about the headline number and more about what management says on the industrial order environment, aerospace programme timing, and whether the acquisition pipeline remains active under current financing conditions. Closest peers EMR and ROK fell 4.4% and 2.1% respectively on the week, underperforming AMETEK's modest 2% decline, which keeps the relative setup broadly intact heading into the release.
See the live data behind this article on ORTEX.
Open AME on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
